Element Biosciences launched Vitari, a high‑throughput sequencing platform the company says can produce 3 terabases per paired‑end 150 bp run in 36 hours and sequence a 30× human genome for approximately $100. The system targets cost‑sensitive large‑cohort and population sequencing workflows. Element positions Vitari to compete on cost and throughput against incumbent platforms, arguing the new instrument changes economics for clinical genomics and large‑scale research. The company highlighted run time and data output as core advantages but will face validation, workflow adoption and ecosystem challenges. If realized at scale, lower per‑genome costs could accelerate population sequencing, diagnostic adoption and long‑read integration strategies across research and clinical markets.